Rallybio RLYB
Rallybio Q2 FY24: revenue $299K; diluted EPS −$0.37
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001739410-24-000115
Key figures from this report
These are the numbers Rallybio reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$299KNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$16.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$0.37No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$16.7MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$10.4MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Brainstorm Cell Therapeutics BCLI public float $10M, Jun 30, 2025
- Kiora Pharmaceuticals KPRX public float $10M, Jun 30, 2025
- Scienture Holdings SCNX public float $10M, Jun 30, 2025
- Phio Pharmaceuticals PHIO public float $11M, Jun 30, 2025
- Palisade Bio PALI public float $11M, Jun 30, 2025
